Previous studies have confirmed that HDAC6 contributed to the pathogenesis of rhabdomyolysis-induced AKI and selective inhibition might be a promising strategy for the treatment of AKI (Shi et al., 2017). The gene discussed is HDAC6; the disease is acute kidney injury.